Search

Your search keyword '"Ballinger M"' showing total 7 results
Start Over Author "Ballinger M" Journal pneumologie
7 results on '"Ballinger M"'

1. IMpower150: analysis of efficacy in patients (pts) with liver metastases (mets)

Author

Reck, M, additional, Jotte, R, additional, Cappuzzo, F, additional, Mok, T, additional, West, H, additional, Nishio, M, additional, Papadimitrakopoulou, VA, additional, Orlandi, F, additional, Stroyakovskii, D, additional, Thomas, C, additional, Nogami, N, additional, Barlesi, F, additional, Lee, A, additional, Shankar, G, additional, Yu, W, additional, Ballinger, M, additional, Bara, I, additional, Sandler, A, additional, and Socinski, M, additional

Published
2020
Full Text
View/download PDF

2. Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the Ph III study OAK

Author

Reinmuth, N, additional, Syrigos, K, additional, Mazieres, J, additional, Cortinovis, D, additional, Dziadziuszko, R, additional, Gandara, D, additional, Conkling, P, additional, Goldschmidt, J, additional, Thomas, CA, additional, Bordoni, R, additional, Kosty, M, additional, Braiteh, F, additional, Hu, S, additional, Ballinger, M, additional, Patel, H, additional, Gandhi, M, additional, and Fehrenbacher, L, additional

Published
2018
Full Text
View/download PDF

3. Blood-Based Biomarkers for Cancer Immunotherapy: Tumor Mutational Burden in Blood (bTMB) is Associated with Improved Atezolizumab (atezo) Efficacy in 2L+ NSCLC (POPLAR and OAK)

Author

Rittmeyer, A, additional, Gandara, D, additional, Kowanetz, M, additional, Mok, T, additional, Fehrenbacher, L, additional, Fabrizio, D, additional, Otto, G, additional, Malboeuf, C, additional, Lieber, D, additional, Paul, SM, additional, Amler, L, additional, Riehl, T, additional, Schleifman, E, additional, Cummings, C, additional, Hegde, PS, additional, Zou, W, additional, Sandler, A, additional, Ballinger, M, additional, and Shames, DS, additional

Published
2018
Full Text
View/download PDF

4. Clinical Efficacy of atezolizumab (atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study

Author

Rittmeyer, A, additional, Gadgeel, S, additional, Kowanetz, M, additional, Zou, W, additional, Hirsch, FR, additional, Kerr, KM, additional, Gandara, D, additional, Barlesi, F, additional, Park, K, additional, McCleland, M, additional, Koeppen, H, additional, Ballinger, M, additional, Sandler, A, additional, and Hegde, PS, additional

Published
2018
Full Text
View/download PDF

5. Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs. docetaxel in 2L/3L NSCLC (POPLAR)

Author

Rittmeyer, A, additional, Smith, D, additional, Vansteenkiste, J, additional, Fehrenbacher, L, additional, Park, K, additional, Mazieres, J, additional, Artal-Cortes, A, additional, Lewanski, C, additional, Braiteh, F, additional, Yi, J, additional, He, P, additional, Zou, W, additional, Waterkamp, D, additional, Ballinger, M, additional, Chen, DS, additional, Sandler, A, additional, and Spira, AI, additional

Published
2017
Full Text
View/download PDF

6. Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC

Author

Schütte, W, additional, Barlesi, F, additional, Park, K, additional, Ciardiello, F, additional, Pawel, J, additional, Gadgeel, S, additional, Hida, T, additional, Kowalski, D, additional, Cobo Dols, M, additional, Cortinovis, D, additional, Leach, J, additional, Polikoff, J, additional, Gandara, DR, additional, Barrios, C, additional, Chen, DS, additional, He, P, additional, Ballinger, M, additional, Waterkamp, D, additional, Sandler, A, additional, and Rittmeyer, A, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results